We have located links that may give you full text access.
Delayed CT to evaluate renal masses incidentally discovered at contrast-enhanced CT: demonstration of vascularity with deenhancement.
Radiology 1999 December
PURPOSE: To determine whether delayed computed tomography (CT) can help confirm vascularity in a neoplasm and differentiate it from a high-density cyst when a well-demarcated homogeneous high-attenuating (> 30-HU) renal mass is incidentally discovered during contrast material-enhanced CT.
MATERIALS AND METHODS: In 25 patients, 26 well-demarcated, homogeneous high-attenuating renal masses (mean diameter, 2.5 cm; range, 1-4 cm) detected at initial postcontrast CT were further evaluated with delayed CT (mean, 38 minutes; range, 15-240 minutes) performed with identical parameters. On both the initial postcontrast and delayed CT scans, region-of-interest measurements were obtained in renal masses and in the gallbladder or low-density renal cysts as controls. Correlation with surgical or additional imaging findings was used to determine proof of diagnosis.
RESULTS: Nine of the masses demonstrated no change in attenuation between initial postcontrast and delayed CT, indicating that they represented avascular lesions consistent with high-density cysts. These cases were confirmed with prior or follow-up imaging studies that demonstrated stability. Seventeen masses (nine surgically proved neoplasms and eight neoplasms that demonstrated interval growth at follow-up or previous CT) demonstrated decreased attenuation at delayed CT compared with initial postcontrast CT, which indicates vascularity.
CONCLUSION: Delayed CT of incidentally discovered well-demarcated homogeneous high-attenuating (> 30-HU) renal masses detected at postcontrast CT enables differentiation of high-density cysts from renal neoplasms by demonstrating deenhancement as a proof of vascularity and, hence, neoplasm.
MATERIALS AND METHODS: In 25 patients, 26 well-demarcated, homogeneous high-attenuating renal masses (mean diameter, 2.5 cm; range, 1-4 cm) detected at initial postcontrast CT were further evaluated with delayed CT (mean, 38 minutes; range, 15-240 minutes) performed with identical parameters. On both the initial postcontrast and delayed CT scans, region-of-interest measurements were obtained in renal masses and in the gallbladder or low-density renal cysts as controls. Correlation with surgical or additional imaging findings was used to determine proof of diagnosis.
RESULTS: Nine of the masses demonstrated no change in attenuation between initial postcontrast and delayed CT, indicating that they represented avascular lesions consistent with high-density cysts. These cases were confirmed with prior or follow-up imaging studies that demonstrated stability. Seventeen masses (nine surgically proved neoplasms and eight neoplasms that demonstrated interval growth at follow-up or previous CT) demonstrated decreased attenuation at delayed CT compared with initial postcontrast CT, which indicates vascularity.
CONCLUSION: Delayed CT of incidentally discovered well-demarcated homogeneous high-attenuating (> 30-HU) renal masses detected at postcontrast CT enables differentiation of high-density cysts from renal neoplasms by demonstrating deenhancement as a proof of vascularity and, hence, neoplasm.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app